Which of the following is true regarding FDA approval of drug labels in relation to state
law claims for failure to warn?
a. FDA approval of the label on a brand-name prescription drug does not preempt state
failure-to-warn claims arising out of injuries caused by the drug nor does FDA approval
of the label preempt state failure-to-warn claims related to approved generic drugs
bearing the FDA-mandated label.
b. FDA approval of the label on a brand-name prescription drug preempts state
failure-to-warn claims arising out of injuries caused by the drug, and federal law also
preempts state failure-to-warn claims related to approved generic drugs as long as they
bear the FDA-mandated label.
c. FDA approval of the label on a brand-name prescription drug preempts state
failure-to-warn claims arising out of injuries caused by the drug, but federal law does
not preempt state failure-to-warn claims related to approved generic drugs bearing the
FDA-mandated label.
d. FDA approval of the label on a brand-name prescription drug does not preempt state
failure-to-warn claims arising out of injuries caused by the drug, but federal law
preempts state failure-to-warn claims related to approved generic drugs as long as they
bear the FDA-mandated label.
Answer:
A guaranty that covers all future obligations of the primary debtor to a lender is referred
to as a __________ guaranty.
a. continuing
b. restricted
c. primary
d. performance